Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2021-07-01 M&A Activity
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
M&A Activity Classification · 1% confidence The document is a press release from MorphoSys AG announcing the expiration of the Hart-Scott-Rodino (HSR) waiting period for its acquisition of Constellation Pharmaceuticals. This announcement relates directly to a merger/takeover activity. The text explicitly mentions the tender offer, the merger agreement, and the expected closing of the transaction. This aligns perfectly with the definition for M&A Activity (TAR). Although it is a news release, the core subject matter is the transaction itself, not just the announcement of a report (RPA) or a general regulatory filing (RNS).
2021-07-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'Total Voting Rights Announcement' released on 30.06.2021, referencing Article 41 of the WpHG (German Securities Trading Act). It explicitly details a 'Type of capital measure' involving a 'Conditional capital increase' and states the 'New total number of voting rights' (32,892,540). This type of announcement, which reports changes in the total number of shares/voting rights due to capital structure events, aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is a regulatory announcement distributed via DGAP, the specific content points directly to a capital structure event rather than a general regulatory filing (RNS).
2021-06-30 English
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Regulatory Filings Classification · 1% confidence The document is a press release dated June 25, 2021, announcing that the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion recommending marketing authorization for Tafasitamab in combination with Lenalidomide in the European Union. This type of announcement, detailing clinical trial results (L-MIND study) and regulatory milestones (CHMP opinion) for a pharmaceutical product, is typically classified as an Earnings Release (ER) if it's a summary of results, or more broadly, a Regulatory Filing (RNS) if it's a general corporate announcement not fitting other specific categories. Since this is a specific announcement about a regulatory/clinical development milestone rather than a comprehensive financial report (10-K, IR) or a general earnings summary (ER), and it is not a proxy statement (DEF 14A) or a management discussion (MDA), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard corporate news, especially those related to drug approvals/opinions. Given the context of pharmaceutical news, it is a significant corporate event announcement.
2021-06-25 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details changes in voting rights percentages held by BlackRock, Inc. in MorphoSys AG, crossing specific thresholds (Section 6 shows a change from 4.86% to 5.06%). This content directly corresponds to the notification requirements for changes in significant share ownership, which matches the definition for Major Shareholding Notification (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the change in major holding percentage, making MRQ the most precise fit over DVA (which is for results of votes) or RNS (which is a fallback).
2021-06-24 English
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
M&A Activity Classification · 1% confidence The document is a press release dated June 16, 2021, announcing that MorphoSys is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals. This action is explicitly related to a merger agreement and involves filing a Schedule TO (Tender Offer Statement) and Constellation filing a Schedule 14D-9. The core subject matter is a takeover bid/merger proposal. According to the definitions, announcements related to merger proposals or takeover bids fall under the 'M&A Activity' category, which corresponds to the code TAR.
2021-06-16 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: MorphoSys AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. This content directly relates to reporting personal share transactions by company directors and executives, which matches the definition for Director's Dealing (DIRS). The document details the person involved (Michael Brosnan), their position, the nature of the transaction (Acquisition), the instrument (ADS), and the price/volume, confirming the classification.
2021-06-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.